Interleukin-12 as a veterinary vaccine adjuvant

An immune adjuvant and veterinary technology, applied in the field of interleukin-12 as a veterinary vaccine adjuvant, can solve the problems of weak immunosuppression and immunogenicity

Inactive Publication Date: 2004-12-15
WYETH LLC
View PDF20 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0026] However, it has not been disclosed or exemplified in the prior art that IL-12 or other immunomodulators can effectively and significantly increase the immunogenicity of weakly immunosuppressive or potentially toxic antigens when specifically co-administered with immune adjuvants

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Effect of Adjuvants on Immunogenicity of Equine Vaccines

[0060] A study was performed to determine the effect of some adjuvants on the immunogenicity of inactivated Streptococcus equi vaccine. For the preparation of the adjuvant, recombinant human IL-12 (4.45 mg / ml), saponin, modified live vaccine stabilizer (SGGK-3, 25% v / v) and bacterial growth medium (modified Todd Hewitt broth, MTHB) stock solution. Three adjuvant blends were made approximately 10 μg IL-12 / dose, 50 μg IL-12 / dose and 10 μg IL-12 + 5 mg saponin / dose.

[0061] To prepare an adjuvant blend containing about 10 μg IL-12 per dose, a rehydration diluent was made by adding about 0.056 ml IL-12 to about 49.719 ml of water sufficient to total 50 ml. Conditioning diluent was then made by adding about 0.056ml IL-12 to about 12.5ml SGGK-3 (25% v / v) mixed with about 37.444ml MTHB.

[0062] To prepare an adjuvant blend containing about 50 μg IL-12 per dose, a rehydration diluent was made by adding about 0.281 ...

Embodiment 2

[0074] Effect of Adjuvants on Immunogenicity of Cattle Vaccines

[0075] A study was performed to determine the effect of some adjuvants on the immunogenicity of a modified live vaccine of BRSV (Bovine Respiratory Syncytial Virus). For the preparation of adjuvants, stock solutions of SP oil adjuvant (5% v / v) and recombinant human IL-12 (about 1260 μg / ml) were used.

[0076] By mixing 20ml Pluronic® L121 (polyoxypropylene-polyoxyethylene block copolymer, commercially available from BASF Corporation, Mount Olive, NJ), 40ml squalane, 3.2ml polysorbate 80 and 936.8ml buffered saline solution, and homogenize the Mix until a stable mass or emulsion forms to prepare SP Oil. Prior to homogenization, the individual components or mixtures were autoclaved. The emulsion was further sterilized by filtration. Formaldehyde and thimerosal were added to a final concentration of 0.2% and a dilution of 1:10000, respectively.

[0077] Adjuvant was produced by adding about 0.278ml IL-12 to abo...

Embodiment 3

[0090] Effect of Adjuvants on Potency of Dog Vaccines

[0091] A study was performed to determine the effect of some adjuvants on the immunogenicity of the monovalent Ehrlichia canis vaccine, an inactivated bacterin. For the preparation of the adjuvant, recombinant human IL-12 (4.45 mg / ml), EMA-31® (1% v / v, with about equal amounts of ethylene and maleic anhydride, a linear lyser with an estimated average molecular weight of about 75,000-100,000 was used. Ethylene / maleic anhydride copolymer, commercially available from Monsanto Co., St. Louis, MO) and Neocryl® A640 (3% v / v, uncondensed aqueous acrylic acid copolymer of acrylic and methacrylic acid mixed with styrene Latex emulsion, pH 7.5, viscosity 100 eps (Brookfield, 25° C.), weighing 8.6 pounds per gallon, supplied with 40 wt. % solids, 38 vol. % solids, and an acid number of 48, commercially available from Polyvinyl Chemicals, Inc. , Wilmington, MA) stock solution. Working solutions of IL-12 were prepared in dilution bu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
softening pointaaaaaaaaaa
melting pointaaaaaaaaaa
decomposition temperatureaaaaaaaaaa
Login to view more

Abstract

This disclosure describes a composition for enhancing the immunogenicity of a veterinary vaccine that comprises a pharmacologically effective amount of an immunomodulator and an immunoadjuvant. Additionally, the disclosure describes a vaccine composition comprising an effective immunizing amount of an antigen, an immunomodulator, an immunoadjuvant and a pharmaceutically acceptable carrier. The compositions may optionally contain conventional, secondary adjuvants or preservatives. The disclosure further describes a unique method for enhancing or accelerating the immunogenicity of weak, immunosuppressive or marginally safe antigens by administering to an avian or mammalian species a pharmacologically effective amount of the aforesaid immunogenicity enhancing composition or an effective immunizing amount of the aforesaid vaccine composition.

Description

[0001] Cross References to Related U.S. Applications [0002] This application claims the benefit of U.S. Provisional Application No. 60 / 322840, filed September 17, 2001, under U.S.C. § 119(e). This prior application is hereby incorporated by reference in its entirety. [0003] A statement about federally funded research or development [0004] none [0005] "Sequence Listing" Reference [0006] none Background of the invention [0007] The present invention relates to a novel combination comprising an immunomodulator in combination with an immunoadjuvant which enhances the immunogenicity or physiological efficacy of an antigen-containing veterinary vaccine and relates to the A novel use of the combination to significantly improve an animal's immune response to an antigen. [0008] Description of related fields [0009] All patents and publications cited in this specification are hereby incorporated by reference in their entirety. [0010] The etiology of many debilitat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00A61K38/21A61K39/00A61K39/09A61K39/118A61K39/12A61K39/23A61K39/39A61P31/00A61P31/04A61P31/12A61P37/04A61P43/00
CPCA61K2039/55522A61K2039/55555A61K2039/55538A61K2039/55577A61K39/39A61P31/00A61P31/04A61P31/12A61P37/04A61P43/00
Inventor H·-J·楚
Owner WYETH LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap